Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 35%
Hold 29%
Sell 0%
Strong Sell 6%

Bulls say

Arvinas Inc. has demonstrated significant increases in the valuations of several key product candidates, including ARV-102, ARV-393, and ARV-806, reflective of their advancing clinical development stages and potential market impact. The company's overall enterprise value has grown to $959 million from $627 million, indicating robust pipeline progress and investor confidence in its innovative protein degradation platform. Furthermore, the integration of promising clinical data, such as enhanced synergy in pan-KRAS degraders, underscores Arvinas's capacity to potentially lead in targeted therapies for oncology, reinforcing a favorable long-term outlook for the company’s stock.

Bears say

Arvinas Inc is experiencing a negative outlook primarily due to a substantial reduction in projected peak revenue for its product vepdegestrant from $641.2 million to $296.9 million, reflecting less favorable economic conditions and competitive pressures in the oncology market. Additionally, the company faces challenges in accessing capital, which could impede critical business functions and delay profitability and cash flow generation. Furthermore, the potential inability to defend its portfolio may result in a loss of market potential for its drug candidates, especially in an increasingly competitive landscape for oncology therapeutics.

Arvinas Inc (ARVN) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 35% recommend Buy, 29% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 17 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.